Last reviewed · How we verify
NCT06381297
Speech in Noise Discrimination Skills in Multiple Sclerosis Patients.
NA trial testing Hearing test in Multiple Sclerosis-Relapsing-Remitting in 60 participants. Completed in 23 April 2023.
23 March 2023
Quick facts
| Lead sponsor | Asuman Kucukoner |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 60 |
| Start date | 9 October 2020 |
| Primary completion | 23 March 2023 |
| Estimated completion | 23 April 2023 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Hearing test
- Speech in noise discrimination test
- Montreal Cognitive Assessment Scale
- Symbol Number Modalities Test (SDMT)
Conditions studied
- Multiple Sclerosis-Relapsing-Remitting — all drugs for Multiple Sclerosis-Relapsing-Remitting →
Sponsor
Asuman Kucukoner
Who can join
Adults 18 to 50, any sex, with Multiple Sclerosis-Relapsing-Remitting. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this clinical trial was to determine the effect of multiple sclerosis on speech reception and discrimination in noise and to compare the effects on the medial olivocochlear reflex, which is thought to affect speech intelligibility in noise, with a control group. The main questions it aims to answer are: Does MS disease affect the ability to discriminate speech in noise? Does MS affect contralateral suppression results assessing medial olivocochlear function? Is there a correlation between the ability to discriminate speech in noise and contralateral suppression skills of MS patients? Data from MS patients and healthy participants will be compared. Thirty relapsing remitting MS patients and 30 healthy participants admitted to the clinic will be evaluated.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06381297
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Hearing test
Trials testing the same drug.
- NCT06036407 — Screening for Hearing Loss After Childhood Cancer · NA · completed
- NCT04832230 — Study of Diagnostic Biomarkers of Acute Acoustic Trauma · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06381297 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Asuman Kucukoner
- Last refreshed: 24 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06381297.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing